Ewing Sarcoma – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Ewing Sarcoma – Pipeline Review, H2 2017’, provides an overview of the Ewing Sarcoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Ewing Sarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ewing Sarcoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Ewing Sarcoma

The report reviews pipeline therapeutics for Ewing Sarcoma by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Ewing Sarcoma therapeutics and enlists all their major and minor projects

The report assesses Ewing Sarcoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Ewing Sarcoma

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Ewing Sarcoma

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Ewing Sarcoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Amgen Inc

AntiCancer Inc

Astellas Pharma Inc

Bristol-Myers Squibb Co

Cebiotex SL

Celgene Corp

Celldex Therapeutics Inc

Eisai Co Ltd

EntreChem SL

Exelixis Inc

Gradalis Inc

Incyte Corp

Ipsen SA

MacroGenics Inc

MediaPharma SRL

Merck & Co Inc

Merrimack Pharmaceuticals Inc

NantKwest Inc

Novartis AG

Oncomatryx Biopharma SL

Oncternal Therapeutics Inc

Pfizer Inc

Pharma Mar SA

Tarveda Therapeutics Inc

Tesaro Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Ewing Sarcoma - Overview 7

Ewing Sarcoma - Therapeutics Development 8

Pipeline Overview 8

Pipeline by Companies 9

Pipeline by Universities/Institutes 12

Products under Development by Companies 13

Products under Development by Universities/Institutes 16

Ewing Sarcoma - Therapeutics Assessment 17

Assessment by Target 17

Assessment by Mechanism of Action 21

Assessment by Route of Administration 24

Assessment by Molecule Type 26

Ewing Sarcoma - Companies Involved in Therapeutics Development 28

Amgen Inc 28

AntiCancer Inc 28

Astellas Pharma Inc 28

Bristol-Myers Squibb Co 29

Cebiotex SL 29

Celgene Corp 30

Celldex Therapeutics Inc 30

Eisai Co Ltd 31

EntreChem SL 31

Exelixis Inc 32

Gradalis Inc 32

Incyte Corp 33

Ipsen SA 33

MacroGenics Inc 34

MediaPharma SRL 34

Merck & Co Inc 34

Merrimack Pharmaceuticals Inc 35

NantKwest Inc 35

Novartis AG 36

Oncomatryx Biopharma SL 36

Oncternal Therapeutics Inc 37

Pfizer Inc 37

Pharma Mar SA 38

Tarveda Therapeutics Inc 38

Tesaro Inc 39

Ewing Sarcoma - Drug Profiles 40

12-B80 - Drug Profile 40

aldoxorubicin hydrochloride - Drug Profile 41

axitinib - Drug Profile 59

Bispecific Monoclonal Antibody to Target GD2 and CD3 for Oncology - Drug Profile 65

cabozantinib s-malate - Drug Profile 66

CEB-01 - Drug Profile 88

Cellular Immunotherapy 2 for Oncology - Drug Profile 89

Cellular Immunotherapy for Oncology - Drug Profile 91

Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile 93

Celyvir - Drug Profile 94

Drugs to Inhibit Sirtuin 1 for Ewing Sarcoma - Drug Profile 95

EC-8042 - Drug Profile 96

EC-8105 - Drug Profile 98

enoblituzumab - Drug Profile 99

everolimus - Drug Profile 102

ganitumab - Drug Profile 114

gemogenovatucel-T - Drug Profile 117

INCB-59872 - Drug Profile 122

ipilimumab + nivolumab - Drug Profile 123

irinotecan hydrochloride - Drug Profile 133

istiratumab - Drug Profile 145

JS-K - Drug Profile 148

KITSG-3227 - Drug Profile 149

KTN-0182A - Drug Profile 150

lenvatinib mesylate - Drug Profile 152

linsitinib - Drug Profile 171

lurbinectedin - Drug Profile 174

Monoclonal Antibody Conjugates for Ewing Sarcoma - Drug Profile 185

Monoclonal Antibody to Inhibit GD2 for Oncology - Drug Profile 186

MPTEM-1ADC - Drug Profile 187

niraparib - Drug Profile 188

NV-101 - Drug Profile 197

NV-103 - Drug Profile 198

OMTX-503 - Drug Profile 199

OMTX-703 - Drug Profile 200

ONC-206 - Drug Profile 201

ONCase-PEG - Drug Profile 202

paclitaxel albumin bound - Drug Profile 203

pazopanib hydrochloride - Drug Profile 216

pembrolizumab - Drug Profile 225

PEN-866 - Drug Profile 294

RNAi Gene Therapy to Inhibit EWS-FLI1 for Ewing Sarcoma - Drug Profile 297

sirolimus albumin-bound - Drug Profile 298

Small Molecules for Ewing Sarcoma - Drug Profile 300

SP-2509 - Drug Profile 301

SP-2577 - Drug Profile 302

talazoparib - Drug Profile 303

TK-216 - Drug Profile 310

Ewing Sarcoma - Dormant Projects 312

Ewing Sarcoma - Discontinued Products 313

Ewing Sarcoma - Product Development Milestones 314

Featured News & Press Releases 314

Appendix 322

Methodology 322

Coverage 322

Secondary Research 322

Primary Research 322

Expert Panel Validation 322

Contact Us 322

Disclaimer 323

List of Tables

List of Tables

Number of Products under Development for Ewing Sarcoma, H2 2017 11

Number of Products under Development by Companies, H2 2017 13

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 14

Number of Products under Development by Universities/Institutes, H2 2017 15

Products under Development by Companies, H2 2017 16

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 17

Products under Development by Companies, H2 2017 (Contd..2), H2 2017 18

Products under Development by Universities/Institutes, H2 2017 19

Number of Products by Stage and Target, H2 2017 21

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 22

Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017 23

Number of Products by Stage and Mechanism of Action, H2 2017 25

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 26

Number of Products by Stage and Route of Administration, H2 2017 28

Number of Products by Stage and Molecule Type, H2 2017 30

Ewing Sarcoma – Pipeline by Amgen Inc, H2 2017 31

Ewing Sarcoma – Pipeline by AntiCancer Inc, H2 2017 31

Ewing Sarcoma – Pipeline by Astellas Pharma Inc, H2 2017 32

Ewing Sarcoma – Pipeline by Bristol-Myers Squibb Co, H2 2017 32

Ewing Sarcoma – Pipeline by Cebiotex SL, H2 2017 33

Ewing Sarcoma – Pipeline by Celgene Corp, H2 2017 33

Ewing Sarcoma – Pipeline by Celldex Therapeutics Inc, H2 2017 34

Ewing Sarcoma – Pipeline by Eisai Co Ltd, H2 2017 34

Ewing Sarcoma – Pipeline by EntreChem SL, H2 2017 35

Ewing Sarcoma – Pipeline by Exelixis Inc, H2 2017 35

Ewing Sarcoma – Pipeline by Gradalis Inc, H2 2017 35

Ewing Sarcoma – Pipeline by Incyte Corp, H2 2017 36

Ewing Sarcoma – Pipeline by Ipsen SA, H2 2017 36

Ewing Sarcoma – Pipeline by MacroGenics Inc, H2 2017 37

Ewing Sarcoma – Pipeline by MediaPharma SRL, H2 2017 37

Ewing Sarcoma – Pipeline by Merck & Co Inc, H2 2017 38

Ewing Sarcoma – Pipeline by Merrimack Pharmaceuticals Inc, H2 2017 38

Ewing Sarcoma – Pipeline by NantKwest Inc, H2 2017 39

Ewing Sarcoma – Pipeline by Novartis AG, H2 2017 39

Ewing Sarcoma – Pipeline by Oncomatryx Biopharma SL, H2 2017 40

Ewing Sarcoma – Pipeline by Oncternal Therapeutics Inc, H2 2017 40

Ewing Sarcoma – Pipeline by Pfizer Inc, H2 2017 41

Ewing Sarcoma – Pipeline by Pharma Mar SA, H2 2017 41

Ewing Sarcoma – Pipeline by Tarveda Therapeutics Inc, H2 2017 41

Ewing Sarcoma – Pipeline by Tesaro Inc, H2 2017 42

Ewing Sarcoma – Dormant Projects, H2 2017 315

Ewing Sarcoma – Discontinued Products, H2 2017 316

List of Figures

List of Figures

Number of Products under Development for Ewing Sarcoma, H2 2017 11

Number of Products under Development by Companies, H2 2017 12

Number of Products under Development by Universities/Institutes, H2 2017 15

Number of Products by Top 10 Targets, H2 2017 20

Number of Products by Stage and Top 10 Targets, H2 2017 20

Number of Products by Top 10 Mechanism of Actions, H2 2017 24

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 24

Number of Products by Routes of Administration, H2 2017 27

Number of Products by Stage and Routes of Administration, H2 2017 27

Number of Products by Molecule Types, H2 2017 29

Number of Products by Stage and Molecule Types, H2 2017 29

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports